$831 Million is the total value of Ikarian Capital, LLC's 140 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACELYRIN INC | $29,680,393 | -51.3% | 2,918,426 | 0.0% | 3.57% | -63.2% | ||
| JASPER THERAPEUTICS INC | $787,561 | -48.9% | 1,125,087 | 0.0% | 0.10% | -61.2% | ||
| TYRA BIOSCIENCES INC | $663,301 | -19.1% | 48,170 | 0.0% | 0.08% | -38.9% | ||
| COGT | COGENT BIOSCIENCES INC | $611,969 | -17.7% | 62,766 | 0.0% | 0.07% | -37.3% | |
| PRQR | PROQR THRAPEUTICS N V | $614,412 | -19.8% | 472,625 | 0.0% | 0.07% | -39.3% | |
| IMTX | IMMATICS N.V | $567,778 | +0.3% | 49,031 | 0.0% | 0.07% | -24.4% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $536,001 | -25.1% | 400,000 | 0.0% | 0.06% | -43.9% | |
| TCON | TRACON PHARMACEUTICALS INC | $492,265 | -38.8% | 2,765,530 | 0.0% | 0.06% | -53.9% | |
| TARA | PROTARA THERAPEUTICS INC | $315,069 | -30.1% | 188,664 | 0.0% | 0.04% | -47.2% | |
| CMMB | CHEMOMAB THERAPEUTICS LTDsponsored ads | $190,986 | -31.7% | 213,392 | 0.0% | 0.02% | -48.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.